Chronic respiratory morbidity and wheeze after preterm birth: a narrative review
Abstract
Preterm birth, defined as birth before 37 weeks of gestation, affects approximately 10% of pregnancies worldwide. Premature birth disrupts normal lung development with those born at earlier gestations most affected. Individuals born preterm are at increased risk of lifelong respiratory morbidity, including recurrent wheeze. As a consequence, affected individuals are often given an incorrect diagnosis of asthma. Asthma is considered a clinical description and is defined as a clinical syndrome characterised by wheeze, breathlessness, and chest tightness, sometimes accompanied by excess cough. This narrative review reports wheeze following preterm birth, considers prematurity-associated lung disease as an alternative diagnosis to asthma and discusses early life exposures as modifiable factors. Furthermore, whether prediction of those at highest risk is possible and what is the optimum management and follow up for affected individuals is discussed. Preterm birth is associated with an approximately double the risk of wheezing in childhood and is particularly common in those born extremely prematurely. While type two (T2) asthma is the predominant asthma phenotype in the general paediatric population, non-T2 mechanisms may be more relevant in those born preterm and hence why they are often unresponsive to standard asthma regimens. Potentially modifiable risk factors are antenatal corticosteroids, in utero growth retardation, chorioamnionitis, maternal antenatal smoking, breast…
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.